Clinical trials: High Grade Gliomas
Glioma
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
This phase I, open-label, dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary…
- Trial name
- NCT02978261
- Testing
- PLB1001
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Glioma
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.
- Trial name
- NCT06413706
- Testing
- Abemaciclib, Temozolomide
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Glioblastoma, Malignant Gliomas
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
- Trial name
- NCT00074646
- Testing
- CC-8490
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG)
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
The objective of this clinical investigation is to assess the safety and performance of the SonoClear® System. Performance will be assessed by analysis of the contrast-to-noise ratio (CNR) and assessment of image quality by using…
- Conditions
- Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG), Glioblastoma
- Trial name
- NCT07042620
- Testing
- SonoClear(R) System
- Where
- 4 sites in Germany
- Volunteers
- 15 people
- Sponsor
- SonoClear AS
Brain Tumor
Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.
This study is designed to assess the safety and tolerability, pharmacokinetic profiles, immunogenicity of GB222 in Chinese patients with relapsed/progressive high-grade glioma; moreover, changes in cerebral edema, changes in KPS…
- Trial name
- NCT04178057
- Testing
- GB222 3mg/kg, GB222 5mg/kg, GB222 7.5mg/kg
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Genor Biopharma Co., Ltd.
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Malignant Melanoma, Medullary Thyroid Cancer
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
- Conditions
- Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma
- Trial name
- NCT02709889
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 30 sites in United States
- Volunteers
- 200 people
- Sponsor
- AbbVie
Osteosarcoma, Medulloblastoma
A Study of Pemetrexed in Children With Recurrent Cancer
To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma…
- Conditions
- Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease)
- Trial name
- NCT00520936
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma.
- Trial name
- NCT03463265
- Testing
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aadi Bioscience, Inc.
Pediatric Tumor of CNS, Pediatric Tumor of Brain
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas.
- Conditions
- Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem
- Trial name
- NCT06357377
- Testing
- NEO100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Neonc Technologies, Inc.
Glioma, Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
- Trial name
- NCT03551249
- Testing
- Focused ultrasound (FUS)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
High Grade Glioma
A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
This is a Phase 1, multicenter, open-label, dose escalation study of intravenous Berubicin in pediatric patients. The purpose of this first-in-pediatrics study is to examine the safety, tolerability, and PK of Berubicin and to…
- Trial name
- NCT05082493
- Testing
- Berubicin Hydrochloride
- Sponsor
- WPD Pharmaceuticals Sp. z o.o.
Glioma Glioblastoma Multiforme, High Grade Glioma (III or IV)
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults.
- Trial name
- NCT06687681
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Marzieh Ebrahimi
Glioblastoma, Diffuse Intrinsic Pontine Glioma
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with recurrent and relapsed diffuse intrinsic pontine glioma, glioblastoma, or grade III or IV glioma.
- Trial name
- NCT02750891
- Testing
- DSP-7888
- Where
- 6 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Glioblastoma, High-grade Glioma
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent…
- Conditions
- Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
- Trial name
- DUAL-CAR-NK-GB (NCT07480941)
- Testing
- Dual-target CAR-NK cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Glioblastoma Multiforme, Anaplastic Astrocytoma
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
The primary objectives of this study are to determine the maximal tolerated dose (MTD) of PAC-1 in combination with temozolomide in patients with high grade glioma: glioblastoma multiforme (GBM) or anaplastic astrocytoma after…
- Trial name
- NCT03332355
- Testing
- PAC-1 Compound
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Vanquish Oncology, Inc.